Table 5.
Expression of LOX was stimulated both by simvastatin and ibandronatea
| Gene expression | U2-Ibn | MG-Ibn | PC-Ibn | MDA-Ibn | U2-Sim | MG-Sim | PC-Sim | MDA-Sim |
|---|---|---|---|---|---|---|---|---|
| LOX basal expression | 9.3 | 9.3 | 8.3 | 10.2 | 8.9 | 9.3 | 7.9 | 10.2 |
| LOX treated expression | 10.0 | 10.0 | 9.8 | 10.3 | 9.5 | 9.6 | 9.9 | 10.6 |
| LOX fold expression | 1.60† | 1.67† | 2.90† | 1.09† | 1.50† | 1.22† | 4.19† | 1.39† |
Abbreviations: U2, U-2 OS; MG, MG-63 osteosarcoma cells; MDA, MDA-MB-231 breast cancer cells; PC, PC-3 prostate cancer cells; Ibn, ibandronate; Sim, simvastatin; C75, inhibitor of fatty acid synthase.
a
All data are derived from Affymetrix ST1.0 expression microarrays, which were used for analysis of mRNA from cell lines after 3 days treatment with respective drugs (150µM ibandronate, 32µM simvastatin, 27µM C75). Expression levels are in relation to the set of standard genes in the microarrays; ∗ = fold downregulation and † = fold upregulation.